NCT00268359View on ClinicalTrials.gov

Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas

PHASE2CompletedINTERVENTIONAL

Enrollment

68

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

August 31, 2006

Study Completion Date

October 31, 2009

Conditions

Brain and Central Nervous System Tumors

Interventions

BIOLOGICAL

bevacizumab

DRUG

irinotecan hydrochloride

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER

NCT00268359 - Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas | Biotech Hunter | Biotech Hunter